Crossmark

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

Crossref DOI link: https://doi.org/10.1007/s40265-019-1057-0

Published Online: 2019-01-30

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pereira, Maria J.

Eriksson, Jan W.
License Information

Text and Data Mining valid from 2019-01-30
More Information

Article History

First Online: 30 January 2019

Compliance with Ethical Standards

:

: No funding was received for the preparation of this manuscript. Funding for our studies in this therapeutic area has been received from The Swedish Diabetes Foundation, EXODIAB, Ernfors Foundation, ALF grants, and AstraZeneca AB.

: JWE has received research grants or honoraria from AstraZeneca, Bristol-Myers-Squibb, Merck Sharpe and Dohme, Bayer, Sanofi, and NovoNordisk. MJP has no conflicts of interest to declare.